Abstract
Ovarian cancer (OC) is the most deadly gynaecological cancer. Despite surgery and first-line chemotherapy, between 60 % and 70 % of OC patients will recur with poor prognosis. Several studies suggest anti-tumour activity of tumour necrosis factor (TNF) when given systematically, but the high toxicity of the drug has limited its use. NGR-human TNF (hTNF) consists of TNF coupled with the peptide NGR that selectively binds to CD13, which is overexpressed on tumour blood vessels. NGR-hTNF is able to increase the intratumoural doxorubicin distribution by altering tumour vasculature. The activity and toxicity profile of NGR-hTNF-doxorubicin combination in recurrent OC will be described.
| Original language | English |
|---|---|
| Pages (from-to) | 9 |
| Number of pages | 1 |
| Journal | European Oncology and Haematology |
| Volume | 9 |
| Issue number | 1 |
| Publication status | Published - 2012 |
Keywords
- Doxorubicin
- NGR-hTNF
- Recurrent ovarian cancer
ASJC Scopus subject areas
- Hematology
- Oncology
Fingerprint Dive into the research topics of 'Ngr-htnf plus doxorubicin in relapsed ovarian carcinoma'. Together they form a unique fingerprint.
Cite this
Lorusso, D., Mancini, M., Sarno, I., Lambiase, A., & Raspagliesi, F. (2012). Ngr-htnf plus doxorubicin in relapsed ovarian carcinoma. European Oncology and Haematology, 9(1), 9.